Tezepelumab regulatory submission accepted and granted FDA priority review for the treatment of patients with asthma. AstraZeneca + Amgen

Despite recent advances in severe asthma, many patients may not qualify for or respond well to current biologic medicines. Patients with severe, uncontrolled asthma experience frequent exacerbations, significant limitations on lung function and a reduced quality of life.

The BLA was based on results from the PATHFINDER clinical trials programme, including results from the pivotal NAVIGATOR Phase III trial. In NAVIGATOR, tezepelumab demonstrated superiority across every primary and key secondary endpoint, compared to placebo, in a broad population of patients with uncontrolled asthma while receiving treatment with medium- or high-dose inhaled corticosteroids (ICS) plus at least one additional controller medicine with or without oral corticosteroids (OCS). There were no clinically meaningful differences in safety results between the tezepelumab and placebo groups in the NAVIGATOR trial. The most frequently reported adverse events with tezepelumab were nasopharyngitis, upper respiratory tract infection and headache. Results from the NAVIGATOR Phase III trial were published in The New England Journal of Medicine in May 2021.

See-

"Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma"- Andrew Menzies-Gow, M.D., Jonathan Corren, M.D., et al.-May 13, 2021 N Engl J Med 2021; 384:1800-1809 . DOI: 10.1056/NEJMoa2034975.